Patent application number | Description | Published |
20090191202 | Methods for manipulating phagocytosis mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 07-30-2009 |
20110014119 | Methods for Manipulating Phagocytosis Mediated by CD47 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc. | 01-20-2011 |
20110015090 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 01-20-2011 |
20120282174 | Synergistic Anti-CD47 Therapy for Hematologic Cancers - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 11-08-2012 |
20130142786 | HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47 - Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies. | 06-06-2013 |
20130244326 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 09-19-2013 |
20140065169 | Methods of Treating Acute Myeloid Leukemia by Blocking CD47 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc. | 03-06-2014 |
20140148351 | Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature - Methods, compositions, and kits are provided for providing a diagnosis, a prognosis, or a prediction of responsiveness to a therapy for a patient with a hematological malignancy. In practicing the subject methods, the expression level of at least one leukemia stem cell (LSC) genes in a tissue sample is assayed to obtain an LSC expression representation. The LSC expression representation is then employed to determine if an individual has a hematological malignancy, to provide a prognosis to a patient with a hematological malignancy, and/or to provide a prediction of the responsiveness of a patient with a hematological malignancy to a therapy. Also provided are screening methods for identifying novel therapies for patients with a hematological malignancy, and compositions and kits for use in these screening methods. | 05-29-2014 |
20140161805 | Methods for Manipulating Phagocytosis Mediated by CD47 - Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable. | 06-12-2014 |
20140161825 | Methods of Treating Acute Myeloid Leukemia by Blocking CD47 - Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc. | 06-12-2014 |
20140255431 | Markers of Acute Myeloid Leukemia Stem Cells - Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets. | 09-11-2014 |
20140271683 | Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related Receptor - Therapeutic and diagnostic methods are provided, which methods relate to the expression of calreticulin on cancer cells and hematopoietic cells. | 09-18-2014 |
20140369924 | SYNERGISTIC ANTI-CD47 THERAPY FOR HEMATOLOGIC CANCERS - Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2. | 12-18-2014 |